Related Experiment Video

Updated: Aug 15, 2026

Visualization of Bacterial Resistance using Fluorescent Antibiotic Probes
08:23

Visualization of Bacterial Resistance using Fluorescent Antibiotic Probes

Published on: March 2, 2020

[Laboratory and clinical studies of cefprozil in pediatric field]

T Nishimura1, K Tabuki, S Aoki

  • 1Department of Pediatrics, Osaka Medical College.

The Japanese Journal of Antibiotics
|November 1, 1992
PubMed

Insights

Cefprozil (CFPZ) demonstrated favorable pharmacokinetics and high efficacy in treating pediatric bacterial infections. This cephalosporin antibiotic showed good tolerability with minimal side effects in clinical studies.

Area of Science:

  • Pharmacology
  • Pediatric Infectious Diseases
  • Clinical Microbiology

Background:

  • Cefprozil (CFPZ) is a novel oral cephalosporin antibiotic.
  • Pediatric bacterial infections require effective and safe treatment options.

Purpose of the Study:

  • To evaluate the pharmacokinetics of cefprozil in pediatric patients.
  • To assess the clinical efficacy and safety of cefprozil in treating various pediatric bacterial infections.

Main Methods:

  • Laboratory and clinical studies were conducted.
  • Cefprozil was administered orally at a single dose of 7.5 mg/kg to two pediatric patients.
  • Clinical efficacy was assessed in 37 pediatric cases with bacterial infections.

Main Results:

  • Peak serum levels of cefprozil ranged from 6.45 to 6.71 µg/ml within 1-2 hours.
  • Urinary excretion rates were approximately 59%, with half-lives between 0.92-1.28 hours.
  • Excellent or good clinical outcomes were observed in all 37 pediatric patients, with no significant adverse effects reported.

Conclusions:

  • Cefprozil exhibits favorable pharmacokinetic properties in children.
  • Cefprozil is an effective and well-tolerated antibiotic for treating pediatric bacterial infections.

More Related Videos

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung09:26

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung

Published on: January 22, 2021

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis07:16

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis

Published on: September 20, 2024

Related Concept Videos

Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Urine Studies II: Urine Culture and Sensitivity Test01:26

Urine Studies II: Urine Culture and Sensitivity Test

A urine culture and sensitivity test is a diagnostic procedure used to identify urinary tract bacterial infections and determine the most effective antibiotics for treatment. This test is generally preferred when a patient shows manifestations of a urinary tract infection, such as frequent or painful urination, cloudy or foul-smelling urine, or lower abdominal pain.Purpose of the TestThe primary goals of a urine culture and sensitivity test are to:Determine the specific bacteria causing the...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...